CERTIM is a cohort created in July 2015 to set up a multidisciplinary follow-up of cancer patients treated with immune checkpoint inhibitors.

From the CERTIM cohort, we conducted a longitudinal, prospective, observational study (ELY) in two tertiary university centers (Cochin hospital and European Georges Pompidou Hospital), which included patients between August 2016 and October 2019 and ended follow-up in April 2020.

Patients were treated with nivolumab, at a dose of 3 mg/kg every 2 weeks, or pembrolizumab, at a dose of 2mg/kg every 3 weeks. The investigators report findings from an evaluation of rest energy expenditure (REE) assessed using indirect calorimetry in the outpatient setting before treatment with checkpoints inhibitors.

Inclusion Criteria:

• 18 years or older
• Stage IV histologically proven Non Small Cell Lung Cancer (NSCLC)
• Monotherapy with nivolumab or pembrolizumab.
• Patients were required to have measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

Exclusion Criteria:

• Active malignancy other than NSCLC,
• ALK or EGFR mutated NSCLC
• Anticancer therapy or surgery within the past 2 weeks or inability to breathe under the calorimetry.

Adult patients with NSCLC initiating nivolumab or pembrolizumab in real-life conditions